These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 1674295)

  • 1. Intramuscular desferrioxamine in patients with Alzheimer's disease.
    Crapper McLachlan DR; Dalton AJ; Kruck TP; Bell MY; Smith WL; Kalow W; Andrews DF
    Lancet; 1991 Jun; 337(8753):1304-8. PubMed ID: 1674295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminum.
    McLachlan DR; Smith WL; Kruck TP
    Ther Drug Monit; 1993 Dec; 15(6):602-7. PubMed ID: 8122302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of deferoxamine mesylate treatment-induced side effects by coadministration of isoniazid in a patient with Alzheimer's disease subject to aluminum removal by ionspecific chelation.
    Kruck TP; Fisher EA; McLachlan DR
    Clin Pharmacol Ther; 1990 Oct; 48(4):439-46. PubMed ID: 2225704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive effects of soy lecithin-derived phosphatidylserine plus phosphatidic acid on memory, cognition, daily functioning, and mood in elderly patients with Alzheimer's disease and dementia.
    Moré MI; Freitas U; Rutenberg D
    Adv Ther; 2014 Dec; 31(12):1247-62. PubMed ID: 25414047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
    Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
    N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal by desferrioxamine of tau protein aggregates following two days of treatment in aluminum-induced neurofibrillary degeneration in rabbit: implications for clinical trials in Alzheimer's disease.
    Savory J; Huang Y; Wills MR; Herman MM
    Neurotoxicology; 1998 Apr; 19(2):209-14. PubMed ID: 9553957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A predictor for side effects in patients with Alzheimer's disease treated with deferoxamine mesylate.
    Kruck TP; Fisher EA; McLachlan DR
    Clin Pharmacol Ther; 1993 Jan; 53(1):30-7. PubMed ID: 8422739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease.
    Johannsen P; Salmon E; Hampel H; Xu Y; Richardson S; Qvitzau S; Schindler R;
    CNS Drugs; 2006; 20(4):311-25. PubMed ID: 16599649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aluminium and the pathogenesis of Alzheimer's disease: a summary of evidence.
    McLachlan DR; Fraser PE; Dalton AJ
    Ciba Found Symp; 1992; 169():87-98; discussion 99-108. PubMed ID: 1490430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial reversal of aluminium-induced neurofibrillary degeneration by desferrioxamine in adult male rabbits.
    Savory J; Herman MM; Erasmus RT; Boyd JC; Wills MR
    Neuropathol Appl Neurobiol; 1994 Feb; 20(1):31-7. PubMed ID: 8208339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.
    Yang YH; Wu MN; Chou PS; Su HC; Lin SH; Sung PS
    Curr Alzheimer Res; 2018 Mar; 15(5):474-481. PubMed ID: 29032750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial.
    Craft S; Claxton A; Baker LD; Hanson AJ; Cholerton B; Trittschuh EH; Dahl D; Caulder E; Neth B; Montine TJ; Jung Y; Maldjian J; Whitlow C; Friedman S
    J Alzheimers Dis; 2017; 57(4):1325-1334. PubMed ID: 28372335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.
    Doody RS; Gavrilova SI; Sano M; Thomas RG; Aisen PS; Bachurin SO; Seely L; Hung D;
    Lancet; 2008 Jul; 372(9634):207-15. PubMed ID: 18640457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
    Aisen PS; Schafer KA; Grundman M; Pfeiffer E; Sano M; Davis KL; Farlow MR; Jin S; Thomas RG; Thal LJ;
    JAMA; 2003 Jun; 289(21):2819-26. PubMed ID: 12783912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.
    Gauthier S; Feldman HH; Schneider LS; Wilcock GK; Frisoni GB; Hardlund JH; Moebius HJ; Bentham P; Kook KA; Wischik DJ; Schelter BO; Davis CS; Staff RT; Bracoud L; Shamsi K; Storey JM; Harrington CR; Wischik CM
    Lancet; 2016 Dec; 388(10062):2873-2884. PubMed ID: 27863809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
    Small G; Erkinjuntti T; Kurz A; Lilienfeld S
    CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
    Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
    Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease.
    Percy ME; Kruck TP; Pogue AI; Lukiw WJ
    J Inorg Biochem; 2011 Nov; 105(11):1505-12. PubMed ID: 22099160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.